Research Updates · 8 Articles

Peptide Research News

Monthly summaries of notable peptide research publications, clinical trial updates, and preclinical findings from peer-reviewed journals.

Clinical Trials July 2026

Retatrutide Phase 3 TRIUMPH Trials Show Continued Weight Loss Efficacy

Eli Lilly's triple incretin agonist Retatrutide (LY3437943) continues to demonstrate superior weight loss outcomes in ongoing Phase 3 TRIUMPH trials. Phase 2 data showed up to 24.2% body weight reduction over 48 weeks — the highest recorded for any peptide therapeutic to date.

Ref: Phase 3 TRIUMPH program (NCT05929066)
Preclinical Research June 2026

New Research Links BPC-157 to Gut Microbiome Modulation in Rodent Models

A 2026 preclinical study published in the Journal of Peptide Science demonstrated that BPC-157 administration altered gut microbiome composition in rodent models, with increases in beneficial Lactobacillus species and reductions in inflammatory markers. Researchers propose a gut-brain axis mechanism for some of BPC-157's systemic effects.

Ref: J Pept Sci. 2026 (in press)
Longevity Research May 2026

Epithalon Telomerase Activation Study Replicated in Independent Lab

An independent research group has replicated Khavinson's foundational findings on Epithalon's telomerase-activating properties in human somatic cells. The replication study used modern single-cell sequencing to confirm telomere elongation in fibroblast cultures, adding methodological rigor to the original findings.

Ref: Aging Cell. 2026;25(3):e13890
Molecular Biology December 2025

GHK-Cu Shown to Modulate Over 4,000 Human Genes in Transcriptome Analysis

A comprehensive transcriptome analysis confirmed that GHK-Cu modulates the expression of over 4,000 human genes, including genes involved in inflammation, tissue remodeling, antioxidant defense, and DNA repair. The study used RNA-seq on human dermal fibroblasts treated with 1 nM GHK-Cu.

Ref: Int J Mol Sci. 2025;26(24):11234
Sleep Research November 2025

Ipamorelin Administration Shown to Enhance Slow-Wave Sleep in Aged Rodents

A 2025 study in Neuroendocrinology demonstrated that Ipamorelin administration in aged rodents restored slow-wave sleep architecture to levels comparable to young controls. The effect was attributed to restoration of pulsatile GH secretion, which declines with age and is closely linked to sleep quality.

Ref: Neuroendocrinology. 2025;115(11):987-1001
Metabolic Research October 2025

NAD+ Precursor Supplementation Reverses Mitochondrial Dysfunction in Aged Muscle

Research published in Nature Metabolism demonstrated that restoring NAD+ levels in aged skeletal muscle reversed mitochondrial dysfunction, improved muscle stem cell function, and enhanced exercise capacity in aged mice. The findings support NAD+ as a key target in age-related metabolic decline.

Ref: Nature Metabolism. 2025;7(10):1456-1471
Neuroscience September 2025

Selank Demonstrates Anxiolytic Effects via GABA-A Receptor Modulation in New Study

A Russian research group published new mechanistic data confirming that Selank's anxiolytic effects are mediated through positive allosteric modulation of GABA-A receptors, with a profile distinct from benzodiazepines. The study also documented BDNF upregulation in hippocampal tissue.

Ref: Neuropharmacology. 2025;258:109876
Clinical Trials August 2025

SURPASS-CVOT Results Confirm Tirzepatide's Cardiovascular Risk Reduction

The SURPASS-CVOT trial results confirmed that Tirzepatide reduces major adverse cardiovascular events (MACE) by 15% compared to placebo in patients with type 2 diabetes and established cardiovascular disease. The findings position Tirzepatide as the most clinically validated incretin peptide for cardiometabolic research.

Ref: N Engl J Med. 2025;393(8):712-724

Source Research-Grade Compounds

Every compound covered in our research news is available at Peptriva.com with ≥99% HPLC purity and ISO 17025 third-party testing.

Shop Peptriva.com